Literature DB >> 16490526

Lipid exudation following plaque radiotherapy for posterior uveal melanoma.

Michael D Mills1, J William Harbour.   

Abstract

PURPOSE: To investigate factors associated with lipid exudation after plaque radiotherapy for uveal melanoma.
DESIGN: Retrospective interventional case series.
METHODS: Records of 139 consecutive uveal melanoma patients treated with I-125 plaque radiotherapy were reviewed. Lipid exudation was the major outcome measured.
RESULTS: Lipid exudation was detected in 19 patients (13.7%). Mean time from plaque therapy to lipid exudation was 10 months (range, 3-23 months). Lipid exudation was associated with younger patient age (P = .0002), increased low-density lipoprotein (P = .004), decreased high-density lipoprotein (P = .026), increased tumor thickness (P = .024), and exudative retinal detachment (P = .016). Patients with lipid exudation had worse visual outcome (P < .0001) and increased neovascular glaucoma (P = .01).
CONCLUSIONS: Lipid exudation after plaque radiotherapy for uveal melanoma is associated with poor ocular outcome. Factors associated with this lipid exudation are distinct from those associated with radiation retinopathy, and they may suggest interventions to combat this complication.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490526     DOI: 10.1016/j.ajo.2005.10.015

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  2 in total

1.  Subretinal lipid exudation associated with untreated choroidal melanoma.

Authors:  C K Minija; Mahesh P Shanmugam
Journal:  Indian J Ophthalmol       Date:  2011 May-Jun       Impact factor: 1.848

Review 2.  New Perspectives for Eye-Sparing Treatment Strategies in Primary Uveal Melanoma.

Authors:  Krzysztof Bilmin; Kamil J Synoradzki; Anna M Czarnecka; Mateusz J Spałek; Tamara Kujawska; Małgorzata Solnik; Piotr Merks; Mario Damiano Toro; Robert Rejdak; Michał Fiedorowicz
Journal:  Cancers (Basel)       Date:  2021-12-28       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.